REG - Redx Pharma plc - RXC004 Phase 1 data to be presented at ESMO 2021

Redx PharmaAnnouncement

13/09/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210913:nRSM4874La&default-theme=true

RNS Number : 4874L  Redx Pharma plc  13 September 2021

REDX PHARMA PLC

("Redx" or "the Company")

 

 

RXC004 Phase 1 monotherapy data to be presented at ESMO Congress 2021

 

Alderley Park, 13 September 2021, Redx Pharma plc (AIM: REDX), the drug
discovery and development company focused on cancer and fibrosis, announces
that data from the Company's RXC004 Phase 1 monotherapy study will be
presented at the forthcoming European Society for Medical Oncology (ESMO)
Congress, 16-21 September 2021.

 

RXC004 is the Company's lead drug candidate and is a potent, orally active
porcupine inhibitor being developed as a targeted therapy for Wnt-ligand
driven cancer. Based on the safety profile observed in the Phase 1 study, Redx
has selected the 2mg dose of RXC004 for its planned Phase 2 monotherapy, proof
of concept clinical trials which are expected to start during the second half
of 2021.

 

The presentation at the ESMO Congress 2021 will be made by the Study Principal
Investigator, Dr Natalie Cook, Consultant Medical Oncologist at the Christie
Hospital NHS Trust, Manchester, UK.

 

 Presentation No:     517MO

 Authors:             N Cook, S Blagden, J Lopez, D Sarker, A Greystoke, N Harris, F Kasmi, A
                      Naderi, G Nintos, A Ortego Franco, R Pihlak, R Shinde, L Goodwin, C Phillips,
                      J Robertson, A Saunders, C Tilston, S Woodcock, R Plummer

 Title:               Phase 1 study of the Porcupine (PORCN) inhibitor RXC004 in patients with
                      advanced solid tumours

 Day/Date:            Monday 20 September 2021

 Presentation Time:   17:50pm to 17:55pm (CET)

 Session Channel:     Channel 3

 Session Title:       Developmental therapeutics

 Session Type:        Mini oral session

 Session Time:        17:30pm to 18:30pm (CET)

 

Redx to host R&D Event

 

Presented data will be discussed by Medical Experts during Redx's online
R&D Event to be held on Monday 11 October 2021 at 1:00pm BST / 8.00am EDT.
The event will also cover the Company's pipeline beyond RXC004.

 

To register for the event, please email redxpharma@fticonsulting.com
(mailto:redxpharma@fticonsulting.com) .

 

 

 For further information, please contact:

 Redx Pharma Plc

 UK Headquarters

 Lisa Anson, Chief Executive Officer          T: +44 1625 469 918
 Karl Hård, Head of Investor Relations
 US Office

 Peter Collum, Chief Financial Officer
 SPARK Advisory Partners (Nominated Adviser)   T: +44 203 368 3550
 Matt Davis/Adam Dawes

 WG Partners LLP (Joint Broker)               T: +44 20 3705 9330
 Claes Spång/Nigel Birks/David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)   T: +44 20 7886 2500
 Rupert Dearden/Freddy Crossley/Emma Earl

 FTI Consulting                               T: +44 20 3727 1000
 Simon Conway/Ciara Martin

 

About Redx Pharma Plc

 

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel
targeted medicines for the treatment of cancer and fibrotic diseases, aiming
initially to progress them to clinical proof of concept, before evaluating
options for further development and potential value creation. Redx's lead
oncology asset, RXC004, is currently in a Phase 1 study in patients with
advanced malignancies and intends to  initiate multiple Phase 2 studies in H2
2021. The Company's selective ROCK2 inhibitor, RXC007, is in development for
idiopathic pulmonary fibrosis and recently commenced a Phase 1 clinical study
in June 2021 where headline results are expected in H1 2022.

 

The Company has a strong track record of discovering new drug candidates
through its core capability of converting medicinal chemistry insights into
differentiated and commercially attractive drug candidates, and has previously
completed preclinical asset transactions with Loxo Oncology (now Eli Lilly),
AstraZeneca and Jazz Pharmaceuticals.

 

To subscribe to RNS announcements from Redx, please visit:
https://www.redxpharma.com/investor-centre/email-alerts
(https://www.redxpharma.com/investor-centre/email-alerts%20)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFLEEEEFSEEU